Polyurethanes for osteoimplants

Patent metadata

Field	Value
Publication number	US-10322209-B2
Application number	US-201815974146-A
Country	US
Kind code	B2
Filing date	May 8, 2018
Priority date	Feb 4, 2003
Publication date	Jun 18, 2019
Grant date	Jun 18, 2019

Abstract

Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.

First claim

What is claimed is:

1. A biodegradable polyurethane composite, comprising: a polyurethane matrix formed by reaction of a polyisocyanate with a hydroxylated biomolecule to form a biodegradable polyurethane polymer; and a reinforcement embedded in the matrix, wherein the reinforcement comprises bone and bone substitutes.

2. A biodegradable polyurethane, formed by reaction of a polyisocyanate with a mixture of hydroxylated biomolecules to form a polyurethane polymer, wherein the mixture of hydroxylated biomolecules comprises polysaccharides; and
lipids or phospholipids.

3. The polyurethane of claim 2 , wherein the polymer is cross-linked.

4. The polyurethane of claim 2 , wherein the polyisocyanate is a diisocyanate.

5. The polyurethane of claim 2 , wherein the polyisocyanate is selected from the group consisting of lysine diisocyanate, toluene diisocyanate, arginine diisocyanate, asparagine diisocyanate, glutamine diisocyanate, hexamethylene diisocyanate, hexane diisocyanate, methylene bis-p-phenyl diisocyanate, isocyanurate polyisocyanates, 1,4-butane diisocyanate, uretdione polyisocyanate, and aliphatic, alicyclic, and aromatic polyisocyanates.

6. The polyurethane of claim 2 , wherein the mixture of biomolecule comprises lecithin.

7. The polyurethane of claim 2 , further comprising polycaprolactone.

8. The polyurethane of claim 2 , further comprising a substance selected from a biomolecule, a bioactive agent, and a small molecule.

9. The polyurethane of claim 8 , wherein the substance is selected from the group consisting of lectins, growth factors, immunosuppressives, and chemoattractants.

10. The polyurethane of claim 2 , further comprising a reinforcement embedded in a matrix of the polyurethane to form a composite material.

11. The polyurethane of claim 10 , wherein the reinforcement comprises a material is selected from the group consisting of calcium carbonate, calcium sulfate, calcium phosphosilicate, sodium phosphate, calcium aluminate, calcium phosphate, calcium carbonate, hydroxyapatite, demineralized bone, mineralized bone, and combinations and modified forms of the above.

12. The polyurethane of claim 10 , comprising at least 10 weight percent of the reinforcement.

13. The polyurethane of claim 10 , comprising at least 30 weight percent of the reinforcement.

14. The polyurethane of claim 10 , comprising at least 50 weight percent of the reinforcement.

15. The polyurethane of claim 10 , comprising at least 70 weight percent of the reinforcement.

16. The polyurethane of claim 10 , wherein the composite material has a wet compressive strength that exceeds the wet compressive strength of the polyurethane alone.

17. The polyurethane of claim 2 , wherein the polyurethane has a wet compressive strength of at least 3 MPa.

18. The polyurethane of claim 2 , wherein the polyurethane has a wet compressive strength of at least 10 MPa.

19. The polyurethane of claim 2 , wherein the polyurethane has a wet compressive strength of at least 50 MPa.

20. The polyurethane of claim 2 , wherein the polyurethane has a wet compressive strength of at least 75 MPa.

Assignees

• Warsaw Orthopedic Inc

Inventors

• Knaack David
• Winterbottom John
• Kaes David R
• Boyce Todd
• Shimp Lawrence A

Classifications

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title

• C08G18/771

  oxygen · CPC title

• C08G18/36

  Hydroxylated esters of higher fatty acids · CPC title

• C08G18/73

  acyclic · CPC title

• C08G18/798

  containing urethdione groups · CPC title